China Universal Asset Management Company’s Atara Biotherapeutics ATRA Stock Holding History

China Universal Asset Management Company’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-104	Closed	-$3.83K	–	434
2023 Q3	$3.83K	Buy	104 +53	+104%	+$2.36K	﹤0.01%	405
2023 Q2	$2.07K	Sell	51 -1	-2%	-$57	﹤0.01%	424
2023 Q1	$3.77K	Buy	52 +13	+33%	+$1.26K	﹤0.01%	394
2022 Q4	$3.16K	Buy	39 +4	+11%	+$417	﹤0.01%	340
2022 Q3	$3K	Buy	+35	New	+$3.93K	﹤0.01%	319

Other funds holding ATRA

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

China Universal Asset Management Company's ATRA Position: Q4 2023 in Review

China Universal Asset Management Company sold out of Atara Biotherapeutics (ATRA) in Q4 2023, closing a stake of 104 shares — an estimated $3.83K sold.

China Universal Asset Management Company first reported a position in ATRA in Q3 2022 and held it in 5 quarters. The position peaked at $3.83K in Q3 2023. 89 funds tracked by Wall St. Rank hold ATRA as of Q4 2023.

China Universal Asset Management Company reported no remaining Atara Biotherapeutics position as of Q4 2023 after selling out during the quarter.
China Universal Asset Management Company sold 104 Atara Biotherapeutics shares in Q4 2023, an estimated $3.83K.
China Universal Asset Management Company first reported a position in Atara Biotherapeutics in Q3 2022 and held it in 5 quarters.
China Universal Asset Management Company's Atara Biotherapeutics position peaked at $3.83K in Q3 2023.
89 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q4 2023.

Based on China Universal Asset Management Company's 13F filing for Q4 2023, filed 24 Jan 2024.